Medication-related osteonecrosis of the jaw-A case report and literature review

Chen Chieh, D. Liao
{"title":"Medication-related osteonecrosis of the jaw-A case report and literature review","authors":"Chen Chieh, D. Liao","doi":"10.17352/2455-5479.000196","DOIUrl":null,"url":null,"abstract":"Osteoporosis is a skeletal disease caused by changes in the structure of the human skeleton, resulting in fragile and easily fractured bones. Because it is more common in postmenopausal women or the elderly, fractures may cause disability in the elderly, resulting in reduced quality of life, bedridden, or increased mortality. Therefore, the treatment of osteoporosis is one of the important issues in today’s aging society. In addition, diseases such as bone metastasis of cancer and multiple myeloma also need to be paid attention to. Drugs for the treatment of osteoporosis have been widely used in the prevention and treatment of osteoporosis because of their inhibitory effect on osteoclast activity, and even become the first-choice drug for bone metastases of some malignant tumors. Drugs for the treatment or prevention of osteoporosis can inhibit osteoclasts, and can also be used to treat hypercalcemia complications of malignant tumors or bone-related systemic diseases. For example, bisphosphonates or monoclonal antibody preparations (eg: Denosumab, Romosozumab, etc.) can resist bone resorption. However, in recent years, the literature pointed out that patients using anti-bone resorption drugs may have adverse reactions to maxillofacial osteonecrosis. Medication-Related Osteonecrosis of the Jaw (MRONJ) may occur in patients with osteoporosis and tumors. Bisphosphonates or synthetic human monoclonal antibodies can inhibit bone resorption and are currently the most commonly used drugs for the treatment of osteoporosis in the world. The literature for nearly 20 years has shown that long-term use of such antiresorptive drugs increases the risk of osteonecrosis of the jaw in the oral cavity. Therefore, MRONJ is still a complication that we must pay attention to. Once MRONJ occurs, it is recommended to refer to an oral surgeon immediately; the current clinical treatment methods include the use of antibacterial mouthwash and drugs to control pain in mild cases, and antibiotics for infection control in moderate cases.","PeriodicalId":87221,"journal":{"name":"Archives of community medicine and public health","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of community medicine and public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/2455-5479.000196","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Osteoporosis is a skeletal disease caused by changes in the structure of the human skeleton, resulting in fragile and easily fractured bones. Because it is more common in postmenopausal women or the elderly, fractures may cause disability in the elderly, resulting in reduced quality of life, bedridden, or increased mortality. Therefore, the treatment of osteoporosis is one of the important issues in today’s aging society. In addition, diseases such as bone metastasis of cancer and multiple myeloma also need to be paid attention to. Drugs for the treatment of osteoporosis have been widely used in the prevention and treatment of osteoporosis because of their inhibitory effect on osteoclast activity, and even become the first-choice drug for bone metastases of some malignant tumors. Drugs for the treatment or prevention of osteoporosis can inhibit osteoclasts, and can also be used to treat hypercalcemia complications of malignant tumors or bone-related systemic diseases. For example, bisphosphonates or monoclonal antibody preparations (eg: Denosumab, Romosozumab, etc.) can resist bone resorption. However, in recent years, the literature pointed out that patients using anti-bone resorption drugs may have adverse reactions to maxillofacial osteonecrosis. Medication-Related Osteonecrosis of the Jaw (MRONJ) may occur in patients with osteoporosis and tumors. Bisphosphonates or synthetic human monoclonal antibodies can inhibit bone resorption and are currently the most commonly used drugs for the treatment of osteoporosis in the world. The literature for nearly 20 years has shown that long-term use of such antiresorptive drugs increases the risk of osteonecrosis of the jaw in the oral cavity. Therefore, MRONJ is still a complication that we must pay attention to. Once MRONJ occurs, it is recommended to refer to an oral surgeon immediately; the current clinical treatment methods include the use of antibacterial mouthwash and drugs to control pain in mild cases, and antibiotics for infection control in moderate cases.
颌骨药物相关性骨坏死1例报告并文献复习
骨质疏松症是一种由人体骨骼结构变化引起的骨骼疾病,导致骨骼脆弱易骨折。由于在绝经后妇女或老年人中更为常见,骨折可能导致老年人残疾,导致生活质量下降,卧床不起或死亡率增加。因此,骨质疏松症的治疗是当今老龄化社会的重要问题之一。此外,癌症骨转移、多发性骨髓瘤等疾病也需要引起重视。治疗骨质疏松的药物因其对破骨细胞活性的抑制作用而广泛应用于骨质疏松的防治,甚至成为一些恶性肿瘤骨转移的首选药物。治疗或预防骨质疏松的药物可抑制破骨细胞,也可用于治疗恶性肿瘤或骨相关全身性疾病的高钙血症并发症。例如,双膦酸盐或单克隆抗体制剂(如:Denosumab、Romosozumab等)可以抵抗骨吸收。然而,近年来有文献指出,使用抗骨吸收药物的患者可能会对颌面部骨坏死产生不良反应。药物相关性颌骨骨坏死(MRONJ)可能发生在骨质疏松症和肿瘤患者中。双膦酸盐或合成人单克隆抗体可抑制骨吸收,是目前世界上治疗骨质疏松症最常用的药物。近20年的文献表明,长期使用此类抗吸收药物会增加口腔内颌骨骨坏死的风险。因此,MRONJ仍然是我们必须重视的并发症。一旦出现MRONJ,建议立即去看口腔外科医生;目前的临床治疗方法包括轻症患者使用抗菌漱口水和药物控制疼痛,中度患者使用抗生素控制感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信